Anti-Diabetes Drugs - Europe | Statista Market Forecast

In Europe, the Anti-Diabetes Drugs market is forecasted to achieve a revenue of US$12.84bn by the year 2024.
This projection indicates an annual growth rate of 7.13% (CAGR 2024-2029), leading to a market volume of US$18.11bn by 2029.
When compared on a global scale, United States is expected to generate the highest revenue, amounting to US$37.84bn in 2024.
Germany has seen a surge in the demand for innovative anti-diabetes drugs, driven by a growing aging population and a strong focus on research and development in the pharmaceutical sector.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Europe has been witnessing steady growth in recent years.

Customer preferences: Patients suffering from diabetes in Europe are increasingly opting for anti-diabetes drugs instead of traditional insulin therapy. This is due to the convenience and effectiveness of anti-diabetes drugs in controlling blood sugar levels. Additionally, the rising prevalence of diabetes in Europe has led to an increase in demand for anti-diabetes drugs.

Trends in the market: Germany is the largest market for anti-diabetes drugs in Europe. The country's aging population and high prevalence of diabetes have contributed to the growth of the market. The UK and France are also significant markets for anti-diabetes drugs in Europe. The UK market is driven by the country's national diabetes prevention program, while the French market is characterized by the increasing use of GLP-1 receptor agonists.

Local special circumstances: In Eastern Europe, the market for anti-diabetes drugs is still in its infancy. However, the region is witnessing increasing demand for these drugs due to rising prevalence of diabetes. In Western Europe, the market is more mature and highly competitive, with several established players dominating the market.

Underlying macroeconomic factors: The growth of the Anti-Diabetes Drugs market in Europe can be attributed to several macroeconomic factors. These include the rising prevalence of diabetes, increasing awareness about the benefits of anti-diabetes drugs, and the availability of advanced drugs that offer better efficacy and fewer side effects. Additionally, favorable government initiatives aimed at promoting diabetes prevention and management have also contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.